Vivian T. Yin, MD, MPH, FRCSC

About Me

I am a surgeon who specializes in treating tumors of the eye socket and surrounding tissue. I have expertise in reconstructing this area after cancer treatment. Whenever possible, I use minimally invasive techniques. This makes surgery easier for my patients and helps them continue to look and feel like themselves.

The possibility of losing an eye is often the most worrisome concern that people have when they come to see me. By using the latest research and innovations I can help my patients keep their eyes and optimize the function. Before surgery we’ll spend a lot of time together, discussing the nature of their disease and all of the possible treatment options. I want my patients to feel empowered to make the best decisions for their unique needs. I work closely with my expert colleagues across many departments to ensure that our patients receive coordinated, comprehensive care.

Outside of the operating room, I am an active researcher. I am studying the genetics of orbital tumors, with a focus on lacrimal gland tumors. My goal is to find mutations that we can target with treatments to help improve outcomes for people with these tumors.

  • Clinical Expertise: Orbital and Ocular Adnexal Tumors; Complex Reconstruction of Eyelids or Orbit; Targeted Therapy for Eyelid and Orbit Cancer; Oculoplastic Surgery Including Eyelids and Lacrimal Surgery
  • Awards and Honors: Best Paper, American Academy of Ophthalmology Annual Meeting (2012); Dr. Sigmund Vaile Award for Excellence in Surgery (2012)
  • Languages Spoken: English; Mandarin
  • Education: MD, University of Toronto; MPH, Johns Hopkins Bloomberg School of Public Health
  • Residencies: Ophthalmology – University of Toronto
  • Fellowships: Ophthalmic Plastic & Reconstruction – MD Anderson Cancer Center
  • Board Certifications: Ophthalmology

See My Colleagues


Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN, Bell D, Frank SJ. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck 2016;38(8):1258-62.

Yin VT, Esmaeli B. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma. Curr Pharm Des 2017;23:655-659. PMID: 27928965

Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol 2015 Apr 30 [Epub ahead of print] PMID:25935097

Yin VT, Warneke C, Merritt H, Esmaeli B. Number of excisions required to obtain clear surgical margins and prognostic value of AJCC T category for patients with eyelid melanoma. Br J Ophthalmol. 2014;98(12):1681-5. [Epub 2014 Jul 22]. PMID:25053759.

Tetzlaff M, Curry J, Yin V, Pattanaprichakul P, Manonukul J, Uiprasertkul M, Manyam G, Wani K, Aldape K, Zhang L, Prieto V, Esmaeli B. Distinct pathways in the pathogenesis of sebaceous carcinoma implicated by differentially express microRNAs. JAMA Ophthalmol. 2015; 133(10):1009-16. [Online First July 23, 2015.] doi:10.1001/jamaophthalmol.2015.2310

Yin VT, Wiraska TA, Esmaeli B. Cutaneous eyelid neoplasm as toxicity of vemurafenib therapy. Ophthal Plast Recontr Surg. 2015;31(4):e112-5. [Epub ahead of print, 2014 May 14]. PMID:24833447.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more Arrow rightAn icon showing an arrow pointing to the right.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.